Uses of Dowanine

Dowanine drug contains the main ingredient Glibenclamide and excipients just enough. The drug is manufactured by Vinh Phuc Pharmaceutical Joint Stock Company (VINPHACO) - VIETNAM, circulated on the market with registration number V160-H12-06.

Dowanine is a drug belonging to the group of hormones and hormones. Dowanine drug is made in the form of tablets with the main ingredient is Glibenclamide, the content of 5mg. Glibenclamide is an active ingredient in the sulfonylurea group that reduces blood glucose levels, because it can increase the sensitivity of pancreatic beta cells to glucose, thereby increasing insulin release. However, the effect of the drug depends on the secretory function of beta cells. In addition, Glibenclamide may increase the level of insulin that exists in the body by reducing the clearance of insulin through the liver.
The mechanism of action of the active ingredient Glibenclamide in the treatment of diabetes is quite complicated. When Glibenclamide was first used in patients with non-insulin dependent diabetes, Glibenclamide increased insulin release in the pancreas. During the first months of treatment, sulfonylureas will increase insulin response. With long-term use, blood insulin levels decrease to pre-treatment levels, but plasma glucose levels remain low.

Dowanine is indicated for use in the treatment of non-insulin dependent type 2 diabetes when diet therapy has not been effective.
In the following cases, the patient is not indicated to prescribe the drug:
The patient is hypersensitive to glibenclamide; Dowanine should not be used in patients with insulin-dependent diabetes mellitus; Contraindicated for patients with severe disorders of glucose metabolism with acidemia; Dowanine should not be used in patients with severe liver or kidney failure, pregnant or lactating women.

Dowanine is taken early in the morning, before meals with the following dosage:
The usual starting dose of Dowanine: 2.5 - 5 mg/day; Usual maintenance dose of Dowanine: 5 - 10 mg/day. The maximum dose of Dowanine is 15 mg/day. The active ingredient Glibenclamide is well absorbed from the gastrointestinal tract, however food and hyperglycemia can reduce the absorption of Glibenclamide (increased blood glucose inhibits gastric and intestinal motility, slowing absorption). . For early optimal glibenclamide plasma concentrations, the most effective time of glibenclamide administration is 30 minutes before a meal, which also ensures a good insulin release during the meal.

Digestive disorders ; Skin hypersensitivity reactions.

Hypoglycemia can occur with an overdose of Dowanine , excessive dieting, alcohol consumption or extreme exercise. Each type of pharmaceutical product when manufactured has a primary purpose of being used to treat a specific disease or condition. That is why patients should only use Dowanine to treat the conditions or conditions specified in the instructions for use. Although Dowanine may have some other effects that are not listed on the label, patients should only use this medicine to treat certain other conditions when directed by their doctor.

The following drugs increase the hypoglycemic effect of Glibenclamide, which in turn may lead to excessive hypoglycaemia when used:
Insulin; Oral diabetes medication; ACE inhibitors ; Anabolic steroids and male sex hormones; Chloramphenicol; Coumarin derivatives; Cyclophosphamide Disopyramide; Fenfluramine; Fenyramidol; Fibrates; Fluoxetine; ifosfamide; MAO inhibitors; Miconazole; Para-aminosalicylic acid; Pentoxifylline (high dose injection); Phenylbutazone; Azapropazone; Oxyphenbutazone; Probenecid; quinolones antibiotics; Salicylates; Sulfinpyrazone; Sulfonamides; Sympathomimetic drugs such as beta-blockers; Guanethidine; Tetracyclines; Tritoqualine; Trofosfamide. The following drugs have the potential to reduce the antidiabetic effect of glibenclamide, thereby causing hyperglycemia:
Acetazolamide; Barbiturates ; Corticosteroids; Diazoxide; Diuretic; Adrenaline; Glucagon; Laxatives (after long-term treatment); nicotinic acid (high dose); Estrogen and progesterone; Phenothiazines; Phenytoin; Thyroid hormone; Rifampicin. H2-receptor antagonists, Clonidine and Reserpine may increase or decrease the hypoglycemic effect of Dowanine. Under the influence of sympathomimetic drugs such as Beta blockers, Clonidine, Guanethidine and Reserpine, signs of sympathetic upregulation of hypoglycemia may decrease or disappear;
Drinking a lot of alcohol at once or drinking alcohol for a long time can increase or decrease the blood sugar lowering effect of Dowanine;
The active ingredient Glibenclamide may decrease or increase the effects of Coumarin derivatives.